Search Results

Market performance Score 25 Neutral

IQVIA Holdings Stock Trails Nasdaq Benchmark in 2024 Amid Sector-Specific Pressures

Mar 10, 2026 14:01 UTC
IQVIA, ^IXIC
Medium term

IQVIA Holdings Inc. (IQVIA) has underperformed the Nasdaq Composite Index (^IXIC) year-to-date, with a 3.2% decline compared to the benchmark’s 6.8% gain through March 10, 2026. The divergence reflects challenges in the healthcare services sector despite broader tech-driven market momentum.

  • IQVIA stock declined 3.2% year-to-date through March 10, 2026, versus Nasdaq’s 6.8% gain
  • S&P Healthcare Services Index down 2.3% YTD, reflecting sector-wide challenges
  • IQVIA reported 4.1% revenue growth in Q4 2025 and adjusted EBITDA margin of 22.7%
  • Forward P/E of 17.3 suggests valuation is modestly elevated relative to sector peers
  • Tech and AI-driven stocks are outperforming healthcare services in Nasdaq-linked indices
  • Market focus shifting toward innovation-led sectors despite IQVIA’s operational stability

IQVIA Holdings Inc. (IQVIA) has lagged behind the Nasdaq Composite Index (^IXIC) in 2026, recording a year-to-date return of -3.2% as of March 10, 2026, while the Nasdaq rose 6.8% over the same period. The performance gap underscores a broader shift in investor sentiment, with technology and growth-oriented equities driving the index’s gains, while healthcare services firms face headwinds from regulatory scrutiny and slower client spending cycles. The underperformance is particularly notable given IQVIA’s long-term positioning as a leader in clinical trial data and pharmaceutical analytics. Despite maintaining steady revenue growth of 4.1% in Q4 2025, the company’s stock has struggled to reflect positive operational metrics, suggesting market concerns around pricing pressures and client retention in the post-pandemic environment. Sector-specific factors have contributed to the divergence. The healthcare services industry has seen a 2.3% average decline in the S&P Healthcare Services Index year-to-date, compared to a 7.1% gain in the S&P 500 Information Technology sector. Analysts note that IQVIA's exposure to long-term pharma contracts and delayed contract renewals has limited upside potential, even as its adjusted EBITDA margin expanded to 22.7% in 2025. Investors are now reassessing the stock’s valuation, with its forward P/E ratio at 17.3, below the S&P 500 average but elevated relative to peers in the healthcare data space. The divergence in performance could signal a rotation toward more cyclical or innovation-driven stocks, particularly in AI and digital health, which are fueling Nasdaq gains.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Intelligence Terminal AI Assistant Trading Challenge Analysis Market News Pricing
Sign In Get Started
Home
Terminal
AI
Markets
Profile